Data capture using digital health technologies has the power to radically improve the quality of your trial outcomes. When properly selected and integrated, devices and wearables can easily and precisely collect vitals, signals, and symptoms to deliver stronger evidence for your trial.
Device selection is part art and part science, requiring tradeoffs between accuracy and reduced patient burden. Don’t let these classic device and wearable missteps occur in your clinical trial.
Not all medical-grade or consumer devices deliver the required level of accuracy.
We carefully select and test all devices to ensure robust biomarkers, outcomes, and endpoints.
Devices designed for precise measurement may not be intuitive or easy to use, leading to low compliance.
We focus on user-friendly devices best suited for your study’s population, condition, and treatment—which translates to more complete data.
Suboptimal device integration can result in missing, erroneous, or superfluous data.
Our effective integration and management ensures that your data is complete, accurate, and able to deliver meaningful endpoints.
ObvioHealth’s ObvioGo® platform is designed with industry-leading capabilities for seamless wearable and sensor integration. That technology, combined with ObvioHealth’s clinical, tech, and data science expertise, delivers the right devices and the right post-processing techniques for optimized data analysis.
Proper device selection is essential to ensuring consistent data capture. So, choosing the right device for your protocol should be a priority.
Capturing a range of symptoms in real time.
Sensors and wearables can complement or replace certain ePRO elements, delivering more and richer real-time data points. They also provide better objectivity, reducing bias.
Symptoms can fluctuate from week to week or even hour to hour. Sensors and wearables enable more frequent measurement, so study teams can quickly identify AEs or SAEs that otherwise might be missed.
In cohorts that include vulnerable populations such as the elderly or those with chronic disease, reduced mobility, or stigmatized diseases, user-friendly devices can increase the likelihood of participation.
When patients share their data from home—either actively or passively—their participation in a trial is less fatiguing. This ease makes it more likely that patients will remain in the study until the end.
ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to enable the majority of patients to recover from illness in their homes rather than being confined to a hospital. Patients used a combination of remote monitoring devices and the ObvioHealth app to record their symptoms.